| Peer-Reviewed

Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B

Received: 22 October 2014     Accepted: 5 November 2014     Published: 10 November 2014
Views:       Downloads:
Abstract

Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.

Published in Science Journal of Clinical Medicine (Volume 3, Issue 6)
DOI 10.11648/j.sjcm.20140306.14
Page(s) 117-123
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2014. Published by Science Publishing Group

Keywords

ALT, HBV DNA Level, HBeAg Status, Liver Histology

References
[1] World Health Organization: WHO: Hepatitis B. Fact Sheet No. 204. (http://www.who.int/mediacentre/factsheets/fs204/en/) (accessed 4 May 2014).
[2] Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT: National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5 Suppl):S4-S12. doi: 10.1002/hep.22946.
[3] Lok AS: Chronic hepatitis B. N Engl J Med. 2002; 346(22):1682-3.
[4] Lee WM: Hepatitis B virus infection. N Engl J Med. 1997; 337(24):1733-45.
[5] Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107.
[6] Sharma SK, Saini N, Chwla Y: Hepatitis B virus: inactive carriers. Virol J. 2005; 2:82.
[7] Martinelli D, Fortunato F, Simsek G, Prato R: Epidemiology and Prevention of Viral Hepatitis B and C. Practical Management of Chronic Viral Hepatitis. Edited by Serviddio G. Croatia: In Tech; 2013;3-18.
[8] Geller SA, Petrovic LM: Chronic Hepatitis (Chronic Necroinflammatory Disease of the Liver)-Grading and Staging. Biopsy Interpretation of the Liver. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2009;97-120
[9] Squadrito G, Spinella R, Raimondo G: The clinical significance of occult HBV infection. Ann Gastroenterol. 2014; 27(1):15-19.
[10] Yim HJ, Lok AS: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173-81.
[11] Kim ES, Seo YS, Keum B, Kim JH, A H, Yim HJ, Kim YS, Jeen YT, Lee HS, Chun HJ, Um SH, Duck Kim C, Ryu HS: The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers. Hepat Mon. 2011; 11(5):351-7.
[12] Ijaz B, Ahmad W, Javed FT, Gull S, Hassan S: Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J. 2011; 8: 86.
[13] European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85.
[14] Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20 Suppl 1:S3-14.
[15] Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG: Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013; 11(3):303-8.e1.
[16] Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B: Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006; 13(10):652-8.
[17] Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H: Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014; 86(1):131-8.
[18] Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008; 6(12):1315-41.
[19] Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1):1-10.
[20] Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology. 2007; 45:507-39.
[21] Keshvari M, Alavian SM, Sharafi H: How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon. 2014; 5:e15285.
[22] McMahon BJ: Chronic hepatitis B virus infection. Med Clin North Am 2014, 98:39-54.
[23] Tong MJ, Trieu J: Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis. 2013; 14(6):311-7
[24] Gastroenterological Society of Australia and Digestive Health Foundation: Australian and New Zealand chronic hepatitis B (CHB) recommendations. Clinical update [webpage on the Internet] Victoria, Australia: The Digestive Health Foundation; 2008. Available from: http://www.gesa.org.au/files/editor_upload/File/Professional/CHB.pdf. Accessed May 5, 2014. http://www.nzsg.org.nz/uploads/Documents/HepBClinical.pdf
[25] Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: comparison of current treatment guidelines. World J Gastroenterol. 2012; 18(42):6106-13.
[26] Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73.
[27] Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ: Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol. 2007; 13(14):2104-7.
[28] Alam S, Ahamd N, Alam K, Mostafa G, Khan M: Correlation between Hepatitis B Viral DNA Load and Extent of Liver Pathology in Patients with Chronic Hepatitis B. Hepatitis Monthly. 2008, 8(3):185-9
[29] Madan K, Batra Y, Jha JK, Kumar S, Kalra N, Paul SB, Singh R, Duttagupta S, Panda SK, Acharya SK: Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.Trop Gastroenterol. 2008; 29(2):84-90.
[30] Peng J, Luo K, Zhu Y, Guo Y, Zhang L, Hou J: Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. Chin Med J (Engl). 2003; 116(9):1312-7.
[31] Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H: Parameters associated with significant liver histological changes in patients with chronic hepatitis B. ISRN Gastroenterol. 2014;2014:913890. doi: 10.1155/2014/913890. eCollection 2014.
[32] Mansour-Ghanaei F, Rafiei R, Joukar F, Naghipour M, Besharati S, Aminian K, Atrkar-Roushan Z: Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province, Iran. Med Sci Monit. 2010; 16(3):BR97-101.
[33] Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, Sivridis E, Papoutselis K: The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol. 2008; 49(6):884-91.
[34] Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002; 36(4):543-6.
[35] Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A: Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57(1):196-202.
[36] Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R: Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J. 2007; 83(975):32-9.
[37] Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002; 36(6):1408-15.
[38] Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ: Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. J Clin Microbiol. 2003; 41(10):4793-5.
[39] Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001; 120(7):1828-53.
[40] Dancygier H: Hepatitis B. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Volume 2. Edited by Dancygier H. Berlin Heidelberg: Springer; 2010:743-80
Cite This Article
  • APA Style

    Ali Koyuncuer. (2014). Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Science Journal of Clinical Medicine, 3(6), 117-123. https://doi.org/10.11648/j.sjcm.20140306.14

    Copy | Download

    ACS Style

    Ali Koyuncuer. Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Sci. J. Clin. Med. 2014, 3(6), 117-123. doi: 10.11648/j.sjcm.20140306.14

    Copy | Download

    AMA Style

    Ali Koyuncuer. Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B. Sci J Clin Med. 2014;3(6):117-123. doi: 10.11648/j.sjcm.20140306.14

    Copy | Download

  • @article{10.11648/j.sjcm.20140306.14,
      author = {Ali Koyuncuer},
      title = {Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B},
      journal = {Science Journal of Clinical Medicine},
      volume = {3},
      number = {6},
      pages = {117-123},
      doi = {10.11648/j.sjcm.20140306.14},
      url = {https://doi.org/10.11648/j.sjcm.20140306.14},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20140306.14},
      abstract = {Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.},
     year = {2014}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B
    AU  - Ali Koyuncuer
    Y1  - 2014/11/10
    PY  - 2014
    N1  - https://doi.org/10.11648/j.sjcm.20140306.14
    DO  - 10.11648/j.sjcm.20140306.14
    T2  - Science Journal of Clinical Medicine
    JF  - Science Journal of Clinical Medicine
    JO  - Science Journal of Clinical Medicine
    SP  - 117
    EP  - 123
    PB  - Science Publishing Group
    SN  - 2327-2732
    UR  - https://doi.org/10.11648/j.sjcm.20140306.14
    AB  - Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.
    VL  - 3
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Department of Pathology, Pathologist, Antakya State Hospital, Hatay, Turkey

  • Sections